When giving 2 mg lorazepam intravenously, what diluent and volume should be used for direct IV administration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Direct IV Administration of Lorazepam 2 mg

For direct IV administration of 2 mg lorazepam, dilute with an equal volume (typically 2 mL of lorazepam with 2 mL of diluent) using Sterile Water for Injection, 0.9% Sodium Chloride, or 5% Dextrose, and inject at a maximum rate of 2 mg per minute. 1

Dilution Requirements

The FDA-approved labeling is explicit about preparation for IV use:

  • Dilution ratio: Equal volume of compatible diluent to lorazepam injection 1
  • Compatible solutions:
    • Sterile Water for Injection, USP
    • 0.9% Sodium Chloride Injection, USP
    • 5% Dextrose Injection, USP 1

Mixing technique: Gently invert the container repeatedly until homogenous—do not shake vigorously as this causes air entrapment 1

Administration Details

  • Maximum injection rate: 2 mg per minute 1
  • Route options: Inject directly into a vein OR into the tubing of an existing IV infusion 1
  • Pre-administration check: Inspect visually for particulate matter and discoloration; do not use if solution is discolored or contains precipitate 1

Clinical Context for 2 mg Dose

The 2 mg dose represents the standard initial dose for sedation and anxiety relief in adults 1. For status epilepticus, the recommended dose is 4 mg given slowly at 2 mg/min, with potential repeat dosing after 10-15 minutes if seizures persist 1.

Critical Safety Considerations

Respiratory support readiness: Have equipment for airway management and artificial ventilation immediately available, as respiratory depression is a significant risk, particularly when combined with other CNS depressants 2, 1. The pediatric emergency literature emphasizes that apnea risk increases substantially when lorazepam is combined with other sedative agents 2.

Monitoring requirements: Continuous oxygen saturation monitoring and vital sign assessment are essential 2.

Common Pitfalls to Avoid

  • Do not administer undiluted IV: The FDA label explicitly requires equal-volume dilution before IV use 1
  • Do not exceed 2 mg/min injection rate: Faster administration increases risk of respiratory depression and hypotension 1
  • Avoid vigorous shaking: This creates air bubbles that can complicate administration 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.